Loading stock data…
MEDP
$471.93+5.13 (+1.10%)
Market OpenUpdated 1:25 PM EDT
Medpace Holdings, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Medpace Holdings, Inc. in the Healthcare sector is trading at $471.93. Wall Street consensus targets $442.83 (12 analysts), implying a -6.2% move over the next 12 months. The stock is currently 25% below its 52-week high of $628.92, remaining 8.0% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 80 is overbought against a weak tape. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply -6.2% downside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 80 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $706.60M↓ | $708.45M↑ | $659.90M↑ | $603.31M↑ | $558.57M |
| Gross Profit | $196.33M↓ | $205.32M↑ | $196.94M↑ | $180.01M↑ | $178.35M |
| Operating Income | $141.50M↓ | $153.27M↑ | $141.81M↑ | $126.33M↑ | $113.52M |
| Net Income | $123.87M↓ | $135.13M↑ | $111.14M↑ | $90.26M↓ | $114.59M |
Peer Comparison
JNJUNHPFE
Fundamentals
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development proc...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
76.95%
Volume
Today's trading volume
95,183
Recent News
How Investors May Respond To Medpace (MEDP) Lawsuits And EVP Shift In Operating Leadership
In early June 2026, Medpace Holdings appointed long-time insider Brad W. Hansman as Executive Vice President, Operations, sharing principal operating officer responsibilities with Susan E. Burwig. At the same time, Medpace is confronting multiple securities class action lawsuits alleging that prior disclosures around book-to-bill guidance, backlog cancellations, and growth expectations were misleading, putting its communication practices under closer scrutiny. We’ll now examine how these...
3 Cash-Producing Stocks with Promising Prospects
Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen their market positions.
Congressman Looking For Dividends? Taylor Ditches 2 Magnificent Seven Stocks For Blue Chips
The trading activity of members of Congress continues to be closely monitored by investors, especially when the moves include Magnificent Seven or large technology stocks. One member of Congress recently sold some Magnificent Seven stocks. Congressman Switches Things Up Rep....
Medpace (MEDP) Stock Slides as Market Rises: Facts to Know Before You Trade
Medpace (MEDP) closed at $445.59 in the latest trading session, marking a -1.3% move from the prior day.
LH or MEDP: Which Is the Better Value Stock Right Now?
LH vs. MEDP: Which Stock Is the Better Value Option?